Search results
Phila. Jury Hits ExxonMobil With $725.5M Verdict Over Carcinogen in Gasoline | The Legal...
Law.com· 3 days agoA Philadelphia state court jury hit ExxonMobil with a $725.5 million verdict Thursday for failing to...
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's...
The Joplin Globe· 14 hours agoSTONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript May 7, 2024 Rigel...
Exxon hit with $725.5 million verdict over mechanic's leukemia diagnosis
Reuters via Yahoo Finance· 3 days agoA Pennsylvania jury ordered ExxonMobil to pay $725.5 million to a former mechanic who claimed toxic chemicals in the company’s gasoline and solvents caused his cancer, according to attorneys ...
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Colorado Springs Gazette· 6 days agoFirst quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 millionExpanded Rigel's portfolio with acquisition of
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 7 days agoFirst-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
NBC 17 Raleigh· 5 days agoMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell...
Nature· 5 days agoT cells are important for the control of acute myeloid leukemia (AML), a common and often deadly malignancy. We observed that some AML ...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 4 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...
Benjamin F. Edwards & Company Inc. Buys Shares of 542 BeiGene, Ltd. (NASDAQ:BGNE)
ETF DAILY NEWS· 20 hours agoBenjamin F. Edwards & Company Inc. purchased a new stake in shares of BeiGene, Ltd. (NASDAQ:BGNE – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities ...